← Leaderboards
Matthew Philip Goetz
Mayo Clinic Rochester
$7,082,692
Attributed
$7,082,692
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.2M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,180,362 · 11
By mechanism
P50$33,377,962 · 9
R01$2,325,750 · 1
P30$476,650 · 1
Top collaborators
- James Newell Ingle4 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Evanthia Galanis$13,573,895
- Richard G Vile$15,977,609
- Fergus Joseph Couch$34,303,973
- Nabila Nora Bennani$914,136
- Amy C Degnim$9,208,153
Others in their field
Top investigators on “Malignant Breast Neoplasm”
- David Heimbrook · Leidos Biomedical Research, Inc.$347,312,063
- Norman Wolmark · Nsabp Foundation, Inc.$122,067,540
- Walter John Curran · Thomas Jefferson University$97,002,422
- Monica M Bertagnolli · Strang Cancer Prevention Center$84,975,759
- Joseph P. Costantino · University Of Pittsburgh At Pittsburgh$68,847,428
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$60,763,376
Research focus
Malignant Breast NeoplasmWomanClinicBreastCollaborationsScientistTranslational ResearchLeadershipMayo Clinic Cancer CenterResearch PersonnelProgramsFundingBaseInnovationMalignant NeoplasmsTumorFutureResearch Project GrantsPositioning AttributeCareerLaboratoriesOrganTamoxifenUnited States National Institutes Of Health
Grant awards (43)
Mayo Clinic Breast Cancer SPORE$2,411,640
P50 · FY2025 · CA · contact PI
Project 2$267,961
P50 · FY2025 · CA · contact PI
Administrative Core$267,960
P50 · FY2025 · CA · contact PI
Career Enhancement Program$267,959
P50 · FY2025 · CA · contact PI
Mayo Clinic Breast Cancer SPORE$2,314,870
P50 · FY2024 · CA · contact PI
Project 2$305,457
P50 · FY2024 · CA · contact PI
Administrative Core$205,157
P50 · FY2024 · CA · contact PI
Career Enhancement Program$90,962
P50 · FY2024 · CA · contact PI
Mayo Clinic Breast Cancer SPORE$2,285,993
P50 · FY2023 · CA · contact PI
Project 2$248,563
P50 · FY2023 · CA · contact PI
Administrative Core$218,064
P50 · FY2023 · CA · contact PI
Women's Cancer Program$98,244
P30 · FY2023 · CA · contact PI
Career Enhancement Program$83,247
P50 · FY2023 · CA · contact PI
Mayo Clinic Breast Cancer SPORE$2,317,281
P50 · FY2022 · CA · contact PI
Project 2$279,341
P50 · FY2022 · CA · contact PI
Administrative Core$187,769
P50 · FY2022 · CA · contact PI
Women's Cancer Program$98,368
P30 · FY2022 · CA · contact PI
Career Enhancement Program$83,256
P50 · FY2022 · CA · contact PI
Mayo Clinic Breast Cancer SPORE$797,371
P50 · FY2021 · CA · contact PI
Core A: Administrative Core$107,464
P50 · FY2021 · CA · contact PI
Women's Cancer Program$98,244
P30 · FY2021 · CA · contact PI
Mayo Clinic Breast Cancer SPORE$2,318,378
P50 · FY2020 · CA · contact PI
Core A: Administrative Core$149,491
P50 · FY2020 · CA · contact PI
Women's Cancer Program$100,686
P30 · FY2020 · CA · contact PI
Mayo Clinic Breast Cancer SPORE$2,272,470
P50 · FY2019 · CA · contact PI
Core A: Administrative Core$140,696
P50 · FY2019 · CA · contact PI
Women's Cancer Program$81,108
P30 · FY2019 · CA · contact PI
Mayo Clinic Breast Cancer SPORE$2,471,635
P50 · FY2018 · CA · contact PI
Core A: Administrative Core$156,211
P50 · FY2018 · CA · contact PI
Mayo Clinic Breast Cancer SPORE$2,438,534
P50 · FY2017 · CA · contact PI
Core A: Administrative Core$151,874
P50 · FY2017 · CA · contact PI
Mayo Clinic Breast Cancer SPORE$2,350,000
P50 · FY2016 · CA · contact PI
Core A: Administrative Core$780,471
P50 · FY2016 · CA · contact PI
Mayo Clinic Breast Cancer SPORE$2,185,001
P50 · FY2015 · CA · contact PI
Mayo Clinic Breast Cancer SPORE$2,783,997
P50 · FY2014 · CA · contact PI
Mayo Clinic Breast Cancer SPORE$2,150,500
P50 · FY2013 · CA · contact PI
Tamoxifen biotransformation pathway pharmacogenomics$225,889
R01 · FY2013 · CA · contact PI
Tamoxifen biotransformation pathway pharmacogenomics$405,232
R01 · FY2012 · CA · contact PI
Endoxifen as a Novel Hormonal Therapy for Breast Cancer$288,389
P50 · FY2012 · CA · contact PI
Tamoxifen biotransformation pathway pharmacogenomics$396,041
R01 · FY2011 · CA · contact PI
Tamoxifen biotransformation pathway pharmacogenomics$257,715
R01 · FY2010 · CA · contact PI
Tamoxifen biotransformation pathway pharmacogenomics$508,888
R01 · FY2009 · CA · contact PI
Tamoxifen biotransformation pathway pharmacogenomics$531,985
R01 · FY2008 · CA · contact PI